LAB 241220 7.50P (LAB241220P7500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

LAB241220P7500

Watchlist

0.00
0.000.00%

15min DelayClose Nov 15 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Seeking AlphaNov 15 15:55 ET
Express News | Standard BioTools - Alex Kim Will No Longer Serve as Co’s Chief Operating Officer, & Co Will Vacate Position of Chief Operating Officer
ReutersNov 7 08:09 ET
Express News | Standard BioTools Appoints Alex Kim as Chief Financial Officer
ReutersNov 7 08:00 ET
Press Release: Standard BioTools Appoints Alex Kim as Chief Financial Officer
Dow JonesNov 7 08:00 ET
Standard BioTools | 10-Q: Q3 2024 Earnings Report
SECNov 6 17:22 ET · Announcements
Earnings Release: Here's Why Analysts Cut Their Standard BioTools Inc. (NASDAQ:LAB) Price Target To US$3.17
Yahoo FinanceNov 2 09:06 ET

Comments

Jaguar8

Sep 24 07:04

NEWS

$Standard BioTools (LAB.US)$
Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), today announced that the SomaScan® 11K Platform now includes protein measurements on a broader range of sample types, including cerebrospinal fluid (CSF), aqueous humor, tissue homogenates and cell lysates. The SomaScan® Platf...

MARKET-TEST-DUMMY

Jul 25 09:18

Insider buying

$Standard BioTools (LAB.US)$

MARKET-TEST-DUMMY

Jun 5 15:13

Keep trying

$Standard BioTools (LAB.US)$

Trytosaveabit

May 28 15:05

Hmm

$Standard BioTools (LAB.US)$ Standard BioTools Purchases the Carterra® Lsa-Xt System to Accelerate Data Delivery and Provide Greater Validation to Somascan Customers

Trytosaveabit

May 8 15:23

Decent

$Standard BioTools (LAB.US)$ Revenue was $46 million, up 81% year-over-year, with impact of SomaScan
assay services, kits and related revenue in 2024; and
-- Ended the quarter with cash, cash equivalents, restricted cash and
short-term investments of $464 million, after accounting for $71 million
cash payments for merger-related expenses, settlement of year-end
operating accruals, debt retirement and completed stock buybacks.